Stock Research: AbCellera Biologics

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

AbCellera Biologics

NasdaqGS:ABCL CA00288U1066
77
  • Value
    100
  • Growth
    63
  • Safety
    Safety
    32
  • Combined
    50
  • Sentiment
    82
  • 360° View
    360° View
    77
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 77 (better than 77% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock AbCellera Biologics are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for AbCellera Biologics. The consolidated Growth Rank has a good rank of 63, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 63% of competitors in the same industry. The consolidated Safety Rank at 100 means that the company has a financing structure that is safer than 100% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 82, which means that professional investors are more optimistic about the stock than for 82% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 32, meaning that the share price of AbCellera Biologics is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 68% of alternative stocks in the same industry. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
32 38 33 89
Growth
63 73 51 3
Safety
Safety
100 100 100 98
Sentiment
82 80 42 85
360° View
360° View
77 77 74 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
73 80 73 65
Opinions Change
57 50 50 50
Pro Holdings
n/a 60 38 97
Market Pulse
59 46 36 54
Sentiment
82 80 42 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
32 38 33 89
Growth
63 73 51 3
Safety Safety
100 100 100 98
Combined
50 50 74 87
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
93 93 93 95
Price vs. Earnings (P/E)
9 5 5 17
Price vs. Book (P/B)
66 83 70 88
Dividend Yield
1 1 1 1
Value
32 38 33 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
96 98 98 1
Profit Growth
32 17 4 56
Capital Growth
8 80 67 42
Stock Returns
79 45 23 3
Growth
63 73 51 3
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
100 100 100 70
Refinancing
85 79 77 71
Liquidity
95 95 95 100
Safety Safety
100 100 100 98

Similar Stocks

Discover high‑ranked alternatives to AbCellera Biologics and broaden your portfolio horizons.

Russel Metals

TSX:RUS
Country: Canada
Industry: Trading & Distribution
Size: Medium
Full Stock Analysis

Canadian Utilities

TSX:CU
Country: Canada
Industry: Multi-Utilities
Size: Medium
Full Stock Analysis

Whitecap Resources

TSX:WCP
Country: Canada
Industry: Oil & Gas Production
Size: Medium
Full Stock Analysis

The North West

TSX:NWC
Country: Canada
Industry: Food Retail
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.